文献速递细菌感染、耐药与抗菌药物

美国感染病学会2022年指南:产超广谱β-内酰胺酶肠杆菌目(ESBL-E)、碳青霉烯耐药肠杆菌目(CRE)及难治性铜绿假单胞菌(DTR-P. aeruginosa)感染的治疗

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
PubMed 文献 · Clin Infect Dis · 2022-01-01

美国感染病学会(IDSA)于2022年发布更新指南,由6名感染病专家组成的小组对2020年9月17日首次发布的ESBL-E、CRE和DTR-P. aeruginosa感染治疗指南进行文献重审和更新。指南针对美国境内已明确病原体及药敏结果的患者,提供首选和替代治疗方案及理由,并简要讨论经验性治疗、疗程等管理考虑,推荐适用于成人和儿童。

要点

  • 指南针对ESBL-E、CRE和DTR-P. aeruginosa感染,提供首选和替代治疗方案及理由。
  • 推荐假定病原体已鉴定且药敏结果已知,适用于成人和儿童。
  • 建议对耐药菌感染的治疗咨询感染病专家。

核心结论

  • 抗微生物耐药领域高度动态,建议对耐药菌感染的治疗咨询感染病专家。
  • 本文件截至2021年10月24日有效。

研究设计与样本

  • 由6名具有耐药菌感染管理专长的感染病专家组成小组,审查、更新并扩展先前制定的关于ESBL-E、CRE和DTR-P. aeruginosa感染治疗的问题和推荐。
  • 因国际间耐药流行病学和特定抗感染药物可及性差异,本文件聚焦于美国境内的感染治疗。

主要发现

  • 提供了首选和替代治疗推荐及相应理由,假定致病菌已鉴定且抗生素药敏结果已知。
  • 简要讨论了经验性治疗、疗程及其他管理考虑。
  • 推荐适用于成人和儿童人群。

临床怎么用

  • 对ESBL-E、CRE和DTR-P. aeruginosa感染,依据本指南选择首选或替代治疗方案(假定病原体已鉴定且药敏结果已知)。
  • 对耐药菌感染的治疗,建议咨询感染病专家。

局限性

  • 因国际间耐药流行病学和特定抗感染药物可及性差异,本文件聚焦于美国境内的感染治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020. Over the past year, there have been a number of important publications furthering our understanding of the management of ESBL-E, CRE, and DTR-P. aeruginosa infections, prompting a rereview of the literature and this updated guidance document. METHODS: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. RESULTS: Preferred and alternative treatment recommendations are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Recommendations apply for both adult and pediatric populations. CONCLUSIONS: The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org/practice-guideline/amr-guidance/.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022. PMID: 35439291. doi:10.1093/cid/ciac268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。